Risklick debuts new AI software that writes clinical trial protocols

Preview

来源: FierceBiotech

Risklick joins a growing number of startups offering AI solutions for various clinical trial operations.

A Swiss startup called Risklick has launched artificial intelligence software for clinical trials that the company claims can reduce development time and costs by as much as 35%, according to an April 23 release.

The software, Protocol AI, is designed to cut down on the time it takes to come up with a study protocol—a process that takes an average of a year in total to complete, by Risklick’s estimates. The company’s technology uses natural language processing and large language models to analyze historical trial data, helps trial sponsors set variables and benchmarks, and then automatically drafts the protocol using generative AI.

Risklick already has deals in place with Swiss biopharma Debiopharm and medical device company ISS AG, also based in Switzerland. The company's software is also being tested by Advanced Clinical, a Chicago-based CRO.

“Protocol AI offers a unique solution in minimizing AI distortions through precise queries and extracting validated data from diverse registries,” Paul Miller, vice president of commercial strategy at Advanced Clinical, said in the Risklick press release. “This transformative capability can revolutionize clinical trial design and enhance industry access to accurate therapeutic data.”

Risklick is a spinout of Switzerland’s University of Bern. The company joins a growing number of startups offering AI solutions for various clinical trial operations, such as Ryght AI, Atomwise and Saama.

Editor's note: A previous version of this article stated that Risklick has established a deal with Advanced Clinical. While Advanced Clinical is interested in Risklick's technology, the companies do not have any agreements in place. The story was updated on April 30, 2024 to clarify their relationship.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。